Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation.
作者信息
Hanania Nicola A, Maspero Jorge F, Halpin David M G, Jackson David J, Panettieri Reynold A, Castro Mario, Domingo Christian, Daizadeh Nadia, Gall Rebecca, Jacob-Nara Juby A, Ortiz Benjamin, Djandji Michel, Rowe Paul J, Deniz Yamo
机构信息
Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA.
Fundación CIDEA, Buenos Aires, Argentina.
出版信息
J Asthma Allergy. 2022 Jun 28;15:851-854. doi: 10.2147/JAA.S354013. eCollection 2022.
Abstract
摘要
相似文献
1
Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation.
J Asthma Allergy. 2022 Jun 28;15:851-854. doi: 10.2147/JAA.S354013. eCollection 2022.
2
Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study.
J Asthma Allergy. 2024 Feb 8;17:81-87. doi: 10.2147/JAA.S425101. eCollection 2024.
3
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.
ERJ Open Res. 2023 Oct 16;9(5). doi: 10.1183/23120541.00037-2023. eCollection 2023 Sep.
4
Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
J Allergy Clin Immunol. 2023 Mar;151(3):747-755. doi: 10.1016/j.jaci.2022.11.021. Epub 2022 Dec 17.
5
Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.
Allergy. 2024 May;79(5):1195-1207. doi: 10.1111/all.16002. Epub 2024 Jan 2.
6
Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE).
J Allergy Clin Immunol Pract. 2024 Dec;12(12):3303-3312. doi: 10.1016/j.jaip.2024.08.038. Epub 2024 Aug 28.
7
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose.
J Allergy Clin Immunol Pract. 2022 Jul;10(7):1835-1843. doi: 10.1016/j.jaip.2022.03.020. Epub 2022 Apr 8.
8
Dupilumab Efficacy and Safety in Children With Moderate to Severe Asthma and High Blood Eosinophils: A Post Hoc Analysis of VOYAGE.
J Allergy Clin Immunol Pract. 2025 Mar;13(3):568-575. doi: 10.1016/j.jaip.2024.11.014. Epub 2024 Nov 28.
9
When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report.
J Med Case Rep. 2024 Jan 31;18(1):63. doi: 10.1186/s13256-023-04255-8.
10
Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma.
Allergy. 2023 Jan;78(1):233-243. doi: 10.1111/all.15456. Epub 2022 Aug 9.
引用本文的文献
1
Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study.
J Asthma Allergy. 2024 Feb 8;17:81-87. doi: 10.2147/JAA.S425101. eCollection 2024.
本文引用的文献
1
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.
ERJ Open Res. 2020 Jan 27;6(1). doi: 10.1183/23120541.00204-2019. eCollection 2020 Jan.
2
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.
3
Asthma outcomes: pulmonary physiology.
J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S65-87. doi: 10.1016/j.jaci.2011.12.986.
4
What are minimal important changes for asthma measures in a clinical trial?
Eur Respir J. 1999 Jul;14(1):23-7. doi: 10.1034/j.1399-3003.1999.14a06.x.
Zotero 插件